Becton, Dickinson and Company (NYSE:BDX) Shares Purchased by Bryn Mawr Capital Management LLC

Bryn Mawr Capital Management LLC boosted its holdings in Becton, Dickinson and Company (NYSE:BDX) by 224.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 23,185 shares of the medical instruments supplier’s stock after buying an additional 16,034 shares during the period. Bryn Mawr Capital Management LLC’s holdings in Becton, Dickinson and Company were worth $5,260,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. boosted its position in shares of Becton, Dickinson and Company by 79.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock worth $720,089,000 after acquiring an additional 1,317,723 shares during the last quarter. Nordea Investment Management AB raised its stake in Becton, Dickinson and Company by 31.0% during the fourth quarter. Nordea Investment Management AB now owns 2,844,566 shares of the medical instruments supplier’s stock worth $647,082,000 after purchasing an additional 673,568 shares during the period. Massachusetts Financial Services Co. MA boosted its holdings in shares of Becton, Dickinson and Company by 9.4% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 5,365,554 shares of the medical instruments supplier’s stock valued at $1,293,635,000 after purchasing an additional 460,440 shares during the last quarter. Vaughan Nelson Investment Management L.P. acquired a new stake in shares of Becton, Dickinson and Company during the 3rd quarter worth $108,243,000. Finally, The Manufacturers Life Insurance Company raised its position in shares of Becton, Dickinson and Company by 62.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 1,107,317 shares of the medical instruments supplier’s stock worth $266,974,000 after buying an additional 424,487 shares during the period. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Up 1.1 %

NYSE BDX opened at $227.56 on Thursday. The stock has a market cap of $65.34 billion, a PE ratio of 37.80, a P/E/G ratio of 1.61 and a beta of 0.40. The business has a 50 day moving average price of $232.85 and a two-hundred day moving average price of $233.38. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $251.99. The company has a quick ratio of 0.63, a current ratio of 1.13 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, beating analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. As a group, sell-side analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be given a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.83%. The ex-dividend date of this dividend is Monday, March 10th. Becton, Dickinson and Company’s payout ratio is 69.10%.

Becton, Dickinson and Company declared that its board has approved a share buyback program on Tuesday, January 28th that permits the company to repurchase 10,000,000 shares. This repurchase authorization permits the medical instruments supplier to repurchase shares of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board believes its shares are undervalued.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Barclays boosted their price target on Becton, Dickinson and Company from $278.00 to $279.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. Piper Sandler increased their target price on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 28th. Finally, StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, February 12th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $278.29.

Insider Buying and Selling

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 700 shares of the company’s stock in a transaction that occurred on Wednesday, February 12th. The stock was sold at an average price of $227.99, for a total value of $159,593.00. Following the transaction, the director now directly owns 36,033 shares of the company’s stock, valued at $8,215,163.67. This represents a 1.91 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Roland Goette sold 4,483 shares of the firm’s stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $221.01, for a total transaction of $990,787.83. Following the sale, the executive vice president now directly owns 24,345 shares of the company’s stock, valued at $5,380,488.45. The trade was a 15.55 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 10,544 shares of company stock worth $2,370,309. 0.36% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.